# A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

> **NCT00073372** · PHASE3 · TERMINATED · sponsor: **Centocor, Inc.** · enrollment: 808 (actual)

## Conditions studied

- Cerebrovascular Accident
- Brain Ischemia
- Acute Disease

## Interventions

- **DRUG:** Abciximab

## Key facts

- **NCT ID:** NCT00073372
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 808 (ACTUAL)
- **Why stopped:** Based on the data and observed benefit-risk profile, the trial's independent oversight committee recommended that enrollment not resume.
- **Last updated:** 2011-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073372, "A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00073372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*